TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05521828

Intervention type: DRUG
Group type: OTHER
Intervention: Follitropin delta (Rekovelle)
Description: 12 mcg/day will be used for ovarian stimulation in both arms

Intervention type: DRUG
Group type: OTHER
Intervention: Follitropin delta (Rekovelle)
Description: 12 mcg/day will be used for ovarian stimulation in both arms

Intervention type: DRUG
Group type: OTHER
Intervention: Duphaston
Description: 20 mg/day will be used for pituitary suppression in both arms

Intervention type: DRUG
Group type: OTHER
Intervention: Duphaston
Description: 20 mg/day will be used for pituitary suppression in both arms

Intervention type: DRUG
Group type: OTHER
Intervention: GnRH agonist (Gonapeptyl)
Description: (2 ampules:0.2 mg) will be used for ovulation triggering in both arms

Intervention type: DRUG
Group type: OTHER
Intervention: GnRH agonist (Gonapeptyl)
Description: (2 ampules:0.2 mg) will be used for ovulation triggering in both arms
Study: NCT05364203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DEEPSEN virtual reality mask
Description: DEEPSEN virtual reality mask with 360 ° vision. The audio-visual content will be chosen by the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEEPSEN virtual reality mask
Description: DEEPSEN virtual reality mask with 360 ° vision. The audio-visual content will be chosen by the patient.
Study: NCT05333705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infusion of natural killer cells
Description: Umbilical cord blood or donated peripheral blood of healthy donors were collected and NK cells were sorted and cultured. NK cell production will be infused after chemotherapy
Study: NCT06221826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexidol
Description: Neurocytoprotector
Study: NCT06066008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-01-L
Description: rAAV-hRS1 intravitreal injection of low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-01-H
Description: rAAV-hRS1 intravitreal injection of high dose
Study: NCT04927585

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: env (A,B,C,A/E)/gag (C) DNA Vaccine
Description: Administered by intramuscular injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: env (A,B,C,A/E)/gag (C) DNA Vaccine
Description: Administered by intramuscular injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp120 (A,B,C,A/E) Protein Vaccine
Description: Administered by intramuscular injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp120 (A,B,C,A/E) Protein Vaccine
Description: Administered by intramuscular injection in the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Administered by intramuscular injection in the deltoid.
Study: NCT06202781

Intervention type: DRUG
Intervention: SOX plus PD-1 inhibitor
Description: S-1, Oxaliplatin and nivolumab/sintilimab

Intervention type: DRUG
Intervention: SOX plus PD-1 inhibitor
Description: S-1, Oxaliplatin and nivolumab/sintilimab
Study: NCT06128603

Intervention type: PROCEDURE
Intervention: laparoscopic pancreaticoduodenectomy
Description: laparoscopic pancreaticoduodenectomy was performed for periampullary benign and malignant diseases. Besides, the surgical video was recorded.
Study: NCT04910711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: Dolutegravir-based antiretroviral therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: Dolutegravir-based antiretroviral therapy
Study: NCT06202781

Intervention type: DRUG
Intervention: SOX plus PD-1 inhibitor
Description: S-1, Oxaliplatin and nivolumab/sintilimab

Intervention type: DRUG
Intervention: SOX plus PD-1 inhibitor
Description: S-1, Oxaliplatin and nivolumab/sintilimab

Intervention type: PROCEDURE
Intervention: Gastroscopic biopsy
Description: Gastroscopy and biopsy

Intervention type: PROCEDURE
Intervention: Gastroscopic biopsy
Description: Gastroscopy and biopsy

Intervention type: PROCEDURE
Intervention: Gastroscopic biopsy
Description: Gastroscopy and biopsy

Intervention type: PROCEDURE
Intervention: Gastroscopic biopsy
Description: Gastroscopy and biopsy
Study: NCT05252663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quake device training
Description: In Quake breathing, patients were advised to take a deep breath and hold it for 3-5 seconds. The patient had the mouthpiece firmly sealed to the lips and were asked to inhale and exhale completely

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional chest physiotherapy
Description: postural drainage - percussion
Study: NCT05777512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Feeds
Description: The participant will receive nutrition via a nasogastric tube. Gastric feedings will be administered as bolus feeds every 3 hours over 1 hour. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Feeds
Description: The participant will receive nutrition via a nasogastric tube. Gastric feedings will be administered as bolus feeds every 3 hours over 1 hour. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jejunal Feeds
Description: The participant will receive nutrition via a nasojejunal tube. Postpyloric feedings will be administered continuously into the jejunum. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jejunal Feeds
Description: The participant will receive nutrition via a nasojejunal tube. Postpyloric feedings will be administered continuously into the jejunum. Infants who are deemed able to advance oral feedings via mouth during the study period will be permitted to do so, and this will be recorded.
Study: NCT05118334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: (IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: (IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: (IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: (IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W)until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: (IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: (IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: (IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: (IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
Study: NCT05574842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double duty interventions using nutrition behavior change communication approach
Description: The packages of the double-duty interventions were modified and adapted from the 2017 WHO policy brief report and Hawkes et al., 2020. These interventions are optimized strong education and nutrition behavior change communication focused on promotion of healthy diets (adequate adolescent nutrition, dietary diversity), physical activity (doing moderate intensity physical exercise, avoiding sitting for log time), prevent undue harm from energy-dense foods (avoiding Junk processed foods, avoiding fizzy sweetened drinks, street fast foods, chips, salt, sugar, fats etc.), and regulations on marketing foods from the customer side (e.g., buying of packed foods frequently).
Study: NCT05008198

Intervention type: OTHER
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation is delivered as part of routine care and is not managed by this observational study.
Study: NCT06523244

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PHOTODYNAMIC THERAPY
Description: Respective photosensitive dye solution is applied on to the surgical site, including all the root surfaces. Vacuum suction is used to remove the excess dye from the site and to prevent ingestion of the dye solution The dye is activated with 810nm diode laser with continuous wave frequency and power of 0.3 W with 400 µm fiber tip for 20 seconds/spot. After this, the area is irrigated with saline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PHOTODYNAMIC THERAPY
Description: Respective photosensitive dye solution is applied on to the surgical site, including all the root surfaces. Vacuum suction is used to remove the excess dye from the site and to prevent ingestion of the dye solution The dye is activated with 810nm diode laser with continuous wave frequency and power of 0.3 W with 400 µm fiber tip for 20 seconds/spot. After this, the area is irrigated with saline.
Study: NCT04575207

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: caFFR
Description: caFFR is a new index of physiological assessment of coronary artery stenosis severity, based on angiographic images. Through two-dimensional analysis and three-dimensional reconstruction of two coronary angiography image series with an angle-off \> 30 degrees, combined with fluid mechanics, TIMI frame counting method, and optimized CFD algorithm, the pressure drop from coronary ostium to every point in the vessel can be obtained, and then the caFFR value of each point in the vessel can be computed. The cutoff value in this trial is caFFR ≤ 0.80 for myocardial ischemia.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FFR
Description: FFR is a widely used, pressure-based functional assessment index of coronary stenoses obtained with an intracoronary pressure wire fitted with pressure sensors. The pressure wire passes through the stenosis and directly measures the pressure distal to the stenosis. FFR value can be obtained by combining the pressure at the coronary ostium and the distal pressure to the stenosis. The cutoff value in this trial is FFR ≤ 0.80 for myocardial ischemia.
Study: NCT05921253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARASYM neuromodulation device
Description: Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PARASYM neuromodulation device
Description: Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the experimental arm for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.
Study: NCT05464615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: We will initially administer 1/5th (56 mg) of the goal dose of amoxicillin (256 mg) by oral route following the procedure outlined below. The total goal dose to be administered is amoxicillin 256 mg (3.2 ml of 400 mg/5 ml). These were numbers that came about for significance in relabeling penicillin allergies in patients in previous studies.
Study: NCT04910711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel implant
Description: Women initiating the levonorgestrel implant

Intervention type: DRUG
Group type: OTHER
Intervention: Levonorgestrel implant
Description: Women initiating the levonorgestrel implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo medroxyprogesterone acetate injection
Description: Women initiating the depo medroxyprogesterone acetate injection

Intervention type: DRUG
Group type: OTHER
Intervention: Depo medroxyprogesterone acetate injection
Description: Women initiating the depo medroxyprogesterone acetate injection
Study: NCT06507488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daphnetin Capsule
Description: Daphnetin, chemically known as 7,8-dihydroxycoumarin, also known as ZuShiMaJiaSu, is a class of coumarin derivatives derived from different Daphnetin genus plant .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a Daphnetin Capsule simulants
Study: NCT05817019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Sodium
Description: Sugammadex Sodium 2mg/kg when TOF \>= 2, postoperative period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine 50µg/kg + glycopyrollate 0.01mg/kg
Description: neostigmine 50µg/kg + glycopyrollate 0.01mg/kg when TOF \>= 2, postoperative period
Study: NCT05111691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling
Study: NCT05624346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep-Breathing Exercises
Description: In addition to routine care in the hospital, the patient will be taught pre-operative breathing exercises. After surgery the patients do deep-breathing exercises every hour.
Study: NCT04828889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anal dilators
Description: Anal sphincter training for relaxation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral internal sphincterotomy
Description: lateral internal sphincterotomy is a firmly established method for treating anal fissures.
Study: NCT05591014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel ROTEM interpretation software
Description: Clinicians will be asked to interpret ROTEM studies before and after exposure to a novel ROTEM interpretation software.
Study: NCT04927585

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
Study: NCT05311696

Intervention type: OTHER
Intervention: psychoeducation
Description: The program consists of psychoeducational material regarding PTSD, demonstration of various stress management techniques, and social cohesion activities

Intervention type: OTHER
Intervention: psychoeducation
Description: The program consists of psychoeducational material regarding PTSD, demonstration of various stress management techniques, and social cohesion activities
Study: NCT04940572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depakine
Description: Refer to arm description.
Study: NCT05851027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0911
Description: Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0911
Description: Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0911
Description: Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
Study: NCT04960592

Intervention type: DEVICE
Intervention: Spinal Cord Stimulation
Description: Temporary implantation of a clinical available neurostimulator.

Intervention type: DEVICE
Intervention: Spinal Cord Stimulation
Description: Temporary implantation of a clinical available neurostimulator.
Study: NCT04884711

Intervention type: OTHER
Intervention: No Interventions. Participants will be using their everyday digital health technologies.
Description: The investigators will be involving older people to understand the barriers \& facilitators of digital health technology adoption for homebound older people. In this process no interventions will be given by us.

Intervention type: OTHER
Intervention: In depth Interviews
Description: In-depth interviews will be conducted to gather lived experiences of homebound older people.

Intervention type: OTHER
Intervention: Focus Group Discussions
Description: Focus Group Discussions will be used to create avenues to enhance dignity and human perspectives in digital designs for older people.
Study: NCT05064956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Ad26.ZEBOV is a non-replicating, monovalent vaccine expressing the full-length Mayinga glycoprotein (GP) of the Ebola virus (formerly known as Zaire ebolavirus), and is produced in human cell line.~Participants will receive a 0.5mL intramuscular injection of Ad26.ZEBOV, at a concentration of 1x10\^11 vp/mL, into the anterolateral deltoid muscle.
Study: NCT04988919

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4D
Description: multi-ingredient supplement mixed with 24 ounces of water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: taste-matched placebo mixed with 24 ounces of water
Study: NCT04255251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diammine Fluoride
Description: Subjects will receive SDF around their crown margins every 6 months for next 3 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnishes
Description: Subjects will receive SDF around their crown margins every 6 months for next 3 years.
Study: NCT06325605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium
Description: 3 capsules, 3 times a day, for 8 consecutive weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Description: In the rTMS treatment, the transcranial magnetic stimulation device with an 8-shaped coil with a diameter of 70mm was placed on the dorsolateral area of the left prefrontal lobe of the patient. The motor threshold was set to 90%. A 10-Hz pulse sequence was applied for 4 secs followed by a 20 secs interval. 10 pulses per train were used, and the total stimulation time was 30mins per day, 4 times a week, for 8 consecutive weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram Oxalate
Description: Oral escitalopram oxalate. The initial dose was 5mg/d, for 7 consecutive days. The dose was increased to 10 mg/d according to the tolerance of the patients for another 7 consecutive days, and then to 20 mg/d according to the patient's condition and tolerance for 8 weeks
Study: NCT06208540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrolysin
Description: Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 20 treatments (for 4 weeks), after which the cycle was repeated again for at least 6 weeks till a maximum of 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: olfactory and gustatory trainings
Description: olfactory and gustatory trainings using oils of strong odors for the same time frame as for the drug intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: olfactory and gustatory trainings
Description: olfactory and gustatory trainings using oils of strong odors for the same time frame as for the drug intervention
Study: NCT04420494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood
Description: The diagnosis is definitely immune cytopenia (IRC), including autoimmune hemolytic anemia (AIHA, Hgb \<100g / L, acquired pure red aplastic anemia (PRCA, Hgb \<100g / L, EVANS syndrome , Hgb \<100g / L and / or platelet count \<30 × 109 / L, or blood cell reduction secondary to immune diseases (the same as the treatment indications, or neutrophils \<0.5 × 109 / L), at least after hormone therapy Patients who are ineffective (did not reach PR after 4 weeks of hormone therapy) or who have not achieved PR after 3-5 mg / kg / d of cyclosporine. These patients would be treated with umbilical cord blood.